Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025

Reuters

10/07

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025

Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus $(HDV)$ infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573952408"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573952408\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573952408?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573952408","market":"us","top_or_hot":-1,"title":"Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-07 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL2tVpRb:1","article_id":"2573952408","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573952408","pubTimestamp":1759838438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on October 07, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","BK4139":"生物科技","BK4535":"淡马锡持仓","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"Vir Biotechnology将在2025年AASLD上展示Tobevibart和Elebsiran治疗慢性δ型肝炎的SOLSTICE 2期试验第48周的阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology to Present Positive Week 48 Results from SOLSTICE Phase 2 Trial of Tobevibart and Elebsiran in Chronic Hepatitis Delta at AASLD 2025\n    \n\n        Vir Biotechnology Inc. has announced that it will present Week 48 endpoint results from the Phase 2 SOLSTICE clinical trial evaluating tobevibart (VIR-3434) alone, or in combination with elebsiran (VIR-2218), in patients with chronic hepatitis delta virus $(HDV)$ infection. The data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place in Washington, D.C., from November 7 to 11, 2025. These results follow previously reported positive data from Week 24 and beyond, demonstrating virologic suppression. In addition, Vir Biotechnology will present information on its ECLIPSE registrational program, which is currently enrolling participants to further evaluate the safety and efficacy of the combination therapy in chronic HDV infection.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251007672641) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}